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Cardiac dysfunctionInhibition of malonyl-coenzyme A decarboxylase (MCD) shifts metabolism from fatty acid towards glucose
oxidation,which has therapeutic potential for obesity andmyocardial ischemic injury. However, ~40% of patients
with MCD deﬁciency are diagnosed with cardiomyopathy during infancy.
Aim: To clarify the link between MCD deﬁciency and cardiac dysfunction in early life and to determine the
contributing systemic and cardiac metabolic perturbations.
Methods and results:MCD knockout mice (−/−) exhibited non-Mendelian genotype ratios (31% fewer MCD−/−)
with deaths clustered around weaning. Immediately prior to weaning (18 days) MCD−/−mice had lower body
weights, elevated body fat, hepatic steatosis and glycogen depletion compared towild-type littermates. MCD−/−
plasmawas hyperketonemic, hyperlipidemic, had 60% lower lactate levels and markers of cellular damage were
elevated. MCD−/− hearts exhibited hypertrophy, impaired ejection fraction and were energetically compro-
mised (32% lower total adenine nucleotide pool). However differences between WT and MCD−/− converged
with age, suggesting that, in surviving MCD−/− mice, early cardiac dysfunction resolves over time. These
observations were corroborated by in silico modelling of cardiomyocyte metabolism, which indicated improve-
ment of the MCD−/−metabolic phenotype and improved cardiac efﬁciency when switched from a high-fat diet
(representative of suckling) to a standard post-weaning diet, independent of any developmental changes.
Conclusions:MCD−/−mice consistently exhibited cardiac dysfunction and severe metabolic perturbations while
on a high-fat, low carbohydrate diet of maternal milk and these gradually resolved post-weaning. This suggests
that dysfunction is a common feature of MCD deﬁciency during early development, but that severity is depen-
dent on composition of dietary substrates.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
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The heart has high energy demands that are primarily met by mito-
chondrial fatty acid oxidation (FAO) [1]. This is regulated at the level
of the outer mitochondrial membrane by the activity of carnitine
palmitoyl transferase 1 (CPT-1), which acts to shuttle cytosolic long
chain acyl-CoA esters into themitochondria [1].Malonyl-CoA is a potent
endogenous allosteric inhibitor of CPT-1 and thereby a key regulator of
fatty acid catabolism. It has a rapid turnover in the heart (t1/2
~ 1.25 min) [2,3] resulting from the balance between synthesis from
acetyl-CoA by acetyl-CoA carboxylase (ACC), and the reverse reaction
catalysed by malonyl-CoA decarboxylase (MCD). By controllingthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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oxidation [1].
Acute pharmacological MCD inhibition has been shown to decrease
fatty acid oxidation and accelerate glucose oxidation in both ex vivo
rat and in vivo pig hearts [4–6]. Furthermore, signiﬁcant reduction of in-
farct size has been reported in MCD deﬁcient mice in which glucose ox-
idation rates were enhanced as a result of the inhibition of fatty acid
oxidation [6,7]. Collectively these ﬁndings support the proposition
that MCD inhibition can be targeted as an effective approach to treating
myocardial ischemia.
While inhibition of MCD and decreasing fatty acid oxidation may
have potential therapeutic beneﬁt in the mature heart, it is not clear
what consequences of MCD inhibition would be in the newborn period.
While foetal hearts rely primarily on glycolysis and lactate oxidation as
sources of energy, shortly after birth there is a rapid maturation of fatty
acid oxidation [4,8]. In contrast, glucose oxidation does notmature until
weaning [9], and in the newborn period the heart actually becomes
more reliant on fatty acid oxidation as an energy source than the adult
heart [8,9]. As a result, MCD inhibition has the potential to decrease car-
diac energy production in the newborn period [1].
Concerns for the general safety ofMCD inhibition arise frompatients
with in-born MCD deﬁciency, a rare autosomal recessive disorder char-
acterized by severe metabolic perturbation in the form of malonic
aciduria and variable presentation of developmental delay, seizures,
and hypoglycaemia [10,11].
In particular, cardiomyopathy develops at an early age in up to 40%
of MCD deﬁcient patients contributing to morbidity and mortality
[12–14]. However, the pathogenesis of cardiomyopathy remains un-
clear andmay not be directly related toMCD deﬁciency since not all pa-
tients are affected.
The aimof this studywas to examine the early cardiac andmetabolic
phenotypes in MCD knockout (MCD−/−) mice to determine whether
functional and metabolic alterations are intrinsic features of chronic
MCD perturbation during infancy. Here we show that MCD−/− mice
universally develop cardiac dysfunction during the peri-weaning period
associatedwith signiﬁcantly increasedmortality and a severemetabolic
phenotype of lipid accumulation and carbohydrate depletion, which
gradually improves with age. This suggests that restricting substrate
plasticity at times of high energy demand and major dietary change is
capable of triggering conditions of energy starvation that are detrimen-
tal to the young heart.
2. Methods
2.1. Mouse colonies
MCD knockout mice (MCD−/−) were imported from the originating
colony at the University of Alberta and backcrossed with C57BL/6J mice
for N6 generations. All mice were generated by heterozygous pair mat-
ing thus littermates could be used as the appropriate wild-type controls
(MCD+/+). Mice were kept under pathogen-free conditions, 12 h light–
dark cycle, controlled temperature (20–22 °C), and fed chow andwater
ad libitum. A breeding diet was used for all dams, LabDiet PicoLab®
Mouse Diet 5058, while weaned mice were gradually introduced to
PicoLab® Rodent diet 5053 over a 6 week period. This protocol is iden-
tical to the originating colony. This investigation conforms to UK Home
Ofﬁce Guidance on the Operation of the Animals (Scientiﬁc Procedures)
Act, 1986.
2.2. In vivo assessment
Micewere imaged and left ventricular (LV) hemodynamicmeasure-
ments (adult mice) performed as previously described [15,16]. Body
composition was analysed by magnetic resonance relaxometry in
conscious restrained mice [15].2.3. Tissue and plasma collection
All mice, knockout (MCD−/−), wild type (MCD+/+) and heterozy-
gous (MCD+/−) were non-fasted, since fasting would have adverse ef-
fects at 18 days of age. Mice were killed by cervical dislocation; the
heart, skeletal muscle (mixed soleus and gastrocnemius) and liver
were excised, snap frozen in liquid nitrogen and stored at−80 °C for
biochemical analyses. Owing to limited tissue availability, body weight
and age matched stock C57BL/6J male mice (Harlan, UK) were used as
controls for themalonyl-CoA level assessment only. Bloodwas collected
from terminally anaesthetized mice into EDTA microcapillary tubes
(Sarstedt, UK) and centrifuged (3000 rpm, 10 min) to obtain plasma.
Concentrations of free fatty acids, triglycerides, cholesterol, high-
density lipoprotein, low-density lipoprotein, total creatine kinase (CK),
lactate, lactate dehydrogenase, and 3-hydroxybutyric acid (ketone
bodies) were measured by the Mouse Biochemistry Laboratory,
Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust.
2.4. Biochemical and gene expression analysis
The activity of the pyruvate dehydrogenase complex (active and
total portion of the enzyme), citrate synthase, triglyceride and glycogen
content in LV, skeletal muscle and liver were determined spectrophoto-
metrically (Online Supplement Methods). Total creatine, total adenine
nucleotide pool (ATP + ADP + AMP) and malonyl-CoA content were
measured by HPLC [4,16]. Total RNA was extracted from heart tissue
of MCD+/+, +/−, −/− (n = 4 per group), survivor MCD−/−, +/+ (n =
9 per group) and messenger RNA levels analysed using qRT-PCR for a
panel of hypertrophic markers and metabolic genes [16] (Online
Supplement Methods).
Liver lipid content was assessed in frozen tissue sections (12 μm),
ﬁxed in 4% PFA, rinsed with 60% triethyl phosphate, stained with oil
red O (0.5%) and counterstained with haematoxylin.
2.5. CardioNet metabolic network reconstruction
In silico simulationswere performed using themetabolic network of
the cardiomyocyte CardioNet (Online Supplement Methods) [17].
2.6. Data analysis and statistics
All data was analysed blind to genotype. Comparison between two
groups was by Student's t-test (Gaussian data distribution), Mann–
Whitney U test (non-Gaussian data distribution) and between 3 groups
by one-way analysis of variance (ANOVA) using Bonferroni's correction
for multiple comparisons. Kaplan–Meier survival curves were com-
pared by log-rank test. Pearson's correlation coefﬁcient was used to as-
sess the relationship between the variables. Data are presented as mean
± S.E.M. Statistical analysis was carried out using GraphPad Prism soft-
ware, v. 5.04. Differences were considered signiﬁcant when P b 0.05.
3. Results
3.1. MCD knockout mice exhibit signiﬁcantly higher early mortality
After establishing the mouse colony using heterozygote pair breed-
ing, non-Mendelian offspring ratios were noted at time of ear-notch
sampling for genotype analysis (18 days of age): from 503 pups ob-
served, the frequency at 18 days was MCD+/− 276: MCD+/+ 173:
MCD−/− 54 (Chi squared = 61; P b 0.0001; Fig. 1A). A further ﬁve
MCD−/−mice were identiﬁed from cadaver remains at between 1 and
16 days of age. Since the expected Mendelian outcome was for 126
MCD−/−, this suggests that approximately 53% ofMCD−/− pups are un-
accounted for, presumably dying either in utero or in post-partum and
cannibalised.
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period. Of the 54 MCD−/− alive at 18 days, n = 18 were culled at this
time point for biochemical analysis (see below), while the remaining
n = 36 were followed into adulthood with 70% dying or euthanized
due to illness over the next 4 weeks (P b 0.0001; Fig. 1B).
The majority of these mice were found dead without obvious symp-
toms despite twice daily observations. A small number were observed
to become symptomatic e.g. pilo-erection, laboured breathing, and un-
responsive to stimuli (see Table 3 of Online Supplement for details).
When anaesthetised with isoﬂurane to perform an echocardiogram,
all mice diedwithinminutes of induction, with contractile function rap-
idly tapering to zero, consistent with acute decompensated heart fail-
ure. Post-mortem examination showed heart-weight ~2-fold higher
than wild-type (P b 0.004) and conﬁrmed milk in the gastric contents
indicating that all mice were suckling normally prior to death.
3.2. Altered gross morphology in young MCD knockout mice
MCD−/− mice were systematically studied at 18 days of age since
this represents a functional and metabolic snap-shot immediately
prior to the period of highest mortality. At 18 days of age, MCD−/−
animals were characterized by a signiﬁcantly reduced body weight
(Fig. 2A) and growth retardation [(tibia length (mm) MCD+/+: 12.4 ±
0.1 (n = 28); MCD+/− 12.3 ± 0.1 (n = 33); MCD−/− 11.8 ± 0.1 (n =
17); p b 0.004)]. Paradoxically, despite lower body weight, percentage
body fat was disproportionately higher in MCD−/− mice versus wild-
types (Fig. 2B), whereas total water was in normal proportion to body
weight (Fig. 2C).
Livers from MCD−/− mice were heavier in proportion to body
weight (Fig. 2D) and were uniformly pale in colour in comparison to
wild-type livers (Fig. 2E). Oil red O staining in histological sections
(Fig. 2F–G) conﬁrmed the presence of severe hepatic steatosis.
3.3. MCD deletion results in pre-weaning cardiac dysfunction
At 18 days of age MCD−/− had LV hypertrophy, as observed from
post-mortem weights normalised to body weight or tibia length (Fig.
3A, B).
This was conﬁrmed at the molecular level by elevated mRNA expres-
sion of classical hypertrophy markers (Fig. 3C). In vivo echocardiography
in 18 day old MCD−/−mice (Fig. 3D) revealed normal LV end-diastolic
chamber volume (Fig. 3F), but with increased end-systolic volume
(Fig. 3E) resulting in signiﬁcantly reduced cardiac ejection fraction
(Fig. 3G).
Heart rates were comparable and there were no signiﬁcant differ-
ences in Doppler ﬂow indices for mitral valve or pulmonary arteryFig. 1. Earlymortality results in non-Mendelian genotype ratios at 18 days of agewith 53% fewerM
while the dotted line shows expected frequency forMCD+/−. From a total of 503 genotyped off-sp
for biochemical phenotyping,with the remaining n=36 contributing to theKaplan–Meier surviva
dying by the age of 50 days.(see Online Supplement Table 4). Simultaneous ECG measurements
showed normal interval durations and no arrhythmic events were
noted in the 18 day old mice (see Online Supplement Table 5).
3.4. Young MCD knockout mice have severely altered metabolic phenotype
As expected,MCD−/−heartswere characterized by elevatedmalonyl-
CoA tissue concentration (C57BL/6J control 2.2 ± 0.3, MCD+/− 5.2 ± 0.3,
MCD−/− 4.9 ± 0.7 nmol/mg protein, P b 0.01, n = 3–4). We sought to
determine if there were changes in energy storage within heart, skeletal
muscle and livers of the MCD−/−mice due to the central role of malonyl
CoA in these tissues to regulate mitochondrial fatty acid metabolism in
response to changes in cellular fuel availability and energy expenditure
[18]. Triglyceride content was 11-fold higher in MCD−/− hearts than in
wild-type controls (Fig. 4A). This signiﬁcant lipid accumulation was ac-
companied by a trend towards decreased myocardial glycogen content
(60% of WT) (Fig. 4D), and a 32% reduction in total adenine nucleotide
(TAN) pool (AMP+ADP+ATP) (Fig. 4G), suggesting an energy depleted
state in young MCD−/− hearts. LV creatine content was not altered
(MCD+/+: 70 ± 4, MCD+/−: 72 ± 6, MCD−/−: 72 ± 3 nmol/g protein;
n= 4). Skeletal muscle fromMCD−/− animals had signiﬁcantly depleted
glycogen content versus MCD+/+ and MCD+/− (Fig. 4E), however, nei-
ther triglycerides (Fig. 4B), the TAN pool (Fig. 4H) nor creatine content
(MCD+/+: 180±13,MCD+/−: 172±5,MCD−/−: 172± 10 nmol/g pro-
tein; n=4)was affected. Similar to LV tissue, chronicMCDdeﬁciencyhad
profound effects on the liver metabolic phenotype, with triglyceride con-
tent 5.9-fold higher (Fig. 4C) and glycogen stores virtually depleted
(Fig. 4F). Liver TAN pool was not affected (Fig. 4I).
MCD−/− hearts were also characterized by decreased citrate
synthase activity (MCD+/+ 274 ± 43; MCD+/− 381 ± 24; MCD−/−
156 ± 26 IU/g wet weight, n = 4, P b 0.05), which may reﬂect changes
in mitochondrial volume. Furthermore, there was no adaptive increase
in pyruvate dehydrogenase activity (Fig. 4J), suggesting that ﬂux
through glucose oxidation was unchanged in the setting of chronically
and severely inhibited fatty acid oxidation.
InMCDdeﬁcient hearts, therewas an increase inmRNA levels ofmi-
tochondrial thioesterase-1 (MTE-1) and PDK4 without changes in ex-
pression for the other genes examined: uncoupling protein 3 (UCP 3),
glucose transporters (GLUT1, GLUT4), fatty acid transporter (CD36),
and mitochondrial fatty acid transporter carnitine palmitoyltransferase
1 (CPT1) (Fig. 4K). There were no changes in the expression of the
markers of apoptosis (caspase 3) and autophagy (Atg3) [19] (Fig. 4K).
Plasma collected from 18 day oldMCD−/−mice wasmilky in appear-
ance due to very high lipid composition: free fatty acids, triglycerides,
total high density lipoprotein and low density lipoprotein cholesterol
were all ~2-fold above wildtype levels (Fig. 5). Circulating ketone bodiesCD−/−mice than expected (A). The dashed line represents expected frequency forMCD−/−,
ring, only 54MCD−/−micewere identiﬁed at 18 days of age. At this point, n= 18were used
l curve (B).Mortality remainedhigh in theperi-weaning periodwith a further 70%ofMCD−/−
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assay and plasma lactate was low in KO, suggesting increased utilization
as an alternative fuel (Fig. 5). Plasma lactate dehydrogenase and totalcreatine kinase levels were both elevated in MCD−/− (Fig. 5), indicating
cellular damage and (combined with elevated ketone bodies) a grossly
catabolic starvation state.
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The nine MCD−/−mice that survived N50 days of age were used for
morphological, in vivo echocardiography and hemodynamic assess-
ment and compared to sex and age matched WT controls. Despite the
signiﬁcant differences in animal gross body morphology observed at
the young age, body weights of adult MCD−/−mice were comparable
to wild-type (Table 1). LV hypertrophy was still detectable by post-
mortem heart weight (Table 1), and when normalised to tibia length
(Fig. 6A) and bodyweight (Table 1). However, hypertrophywas no lon-
ger evident at the molecular level, with mRNA of key hypertrophic
markers no longer signiﬁcantly elevated above wild-type (Fig. 6B).
When indexed LV weight was plotted against age there was a
clear convergence between knockout and wild-type with time, indicat-
ing a gradual normalization of LV hypertrophy with increasing age (Fig.
6C, D).
MCD−/− adult mice had normal LV chamber areas, LV pressures and
heart rate (Table 1), but the rate of pressure development and relaxa-
tion was impaired (dP/dtmax and Tau) (Table 1). ECG interval parame-
ters were normal with the exception of a slightly prolonged QRS
interval in MCD−/−, which most likely reﬂects residual LV hypertrophy
in these animals. An irregular R–R interval was noted in n= 1MCD+/+
and n = 1 MCD−/− during echocardiography, but was not observed
during subsequent LV cannulation (Online Supplement Table 6).
Again, differences between MCD−/− and MCD+/+ converged with
age, suggesting a gradual attenuation of the early cardiac dysfunction.
In support of this, there was a marked improvement in metabolicphenotype in older mice: 11.5 fold elevation in the heart TAG content
observed in the pre-weaning MCD knockout animals was reduced to
1.3 fold difference in the young adult hearts (Fig. 6E), liver weight to
body weight was comparable to wild-types with normal colouration
(Table 1), and the 32% reduction in cardiac TAN pool became an 18%
difference (Fig. 6F).
3.6. In silico modelling of MCD−/−metabolism with high and low fat diets
Our experimental data suggests normalization of cardiac and meta-
bolic phenotypes as MCD−/− reach adulthood. However, the very high
levels of earlymortality severely limited our ability to perform addition-
al experiments in adult mice andwe therefore estimatedmetabolic ﬂux
rates by using the metabolic network reconstruction of the human
cardiomyocyte CardioNet [17]. In particular, we sought to determine
whether the major change in dietary composition that occurs at
weaning could contribute to the observed phenotypic resolution. Simu-
lations of MCD deletion were run under conditions of high dietary fat to
mirror the high-fat composition ofmaternalmilk and re-run under low-
fat availability to reﬂect standardmouse chow consumed post-weaning
(Supplementary Table 2).
High-fat simulations re-capitulated the experimentalﬁndings show-
ing overt triacylglyceride accumulation with MCD deﬁciency (Fig. 7A).
Furthermore, MCD insufﬁciency increased the ﬂux rate for glycogen
degradation which agrees with depletion of glycogen content observed
experimentally (Fig. 7B). Despite the increased availability of fatty acids
with high-fat diet, the contribution of palmitic acid to β-oxidation in
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n = 9, MCD+/− n = 4, MCD−/− n = 4). (F) Liver glycogen content (MCD+/+ n = 5, MCD+/− n = 4, MCD−/− n = 5). (G) LV total adenine nucleotide (TAN) pool (all groups n = 4).
(H) Skeletalmuscle total adenine nucleotide pool (all groups n=4). (I) Liver total adenine nucleotide pool (all groups n=4). (J) Pyruvate dehydrogenase complex activity [PDHtotal:PDH-
active ratio: MCD+/+ (n= 8), MCD+/− (n= 8), MCD−/− (n= 4)]. (K) Cardiac expression of genes involved in the regulation of fatty acid oxidation (n= 4 per group), apoptosis and au-
tophagy. * denotes P b 0.05 and ** denotes P b 0.01 for MCD+/+ or MCD+/− versus MCD−/− group.
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bution of glucose to acetyl-CoA production was predicted to be higher
(Fig. 7D). Of particular note, metabolic changes caused by the combina-
tion of MCD deﬁciency and high-fat diet translated into a greatly re-
duced cardiac efﬁciency, which dramatically improved when switched
to a low-fat diet (Fig. 7E).MCD+/− in silico modelling data revealed that in early life, under
high fat diet conditions, heterozygous mice have a metabolic proﬁle
comparable toMCD+/+ in terms of fatty acid oxidation (Fig. 7C), glucose
vs. fatty acid contribution (Fig. 7D) and cardiac efﬁciency (Fig. 7E) thus
recapitulating our experimental ﬁndings. However, long term theymay
develop an intermediate phenotype characterized by mild fatty acid
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and glycogen breakdown.
4. Discussion
The major ﬁnding of this study is that cardiac dysfunction was uni-
versally observed in all MCD knockout mice, resulting in high peri-
natal and peri-weaning mortality. We believe that death was due to
acute decompensatedheart failure since animals thatwere found symp-
tomatic had laboured breathing and pump failure, followed by death,
whichwas directly observed usingultrasound in the absence of arrhyth-
mia on the ECG. However, we cannot rule out a whole body metabolic
component. The fact that cardiac function was only mildly impaired at
18 days of age suggests that decompensation can occur very rapidly in
the mouse, and this is consistent with our own observations using sur-
gical models of heart failure.
Our results further suggest that cardiac metabolic impairment pre-
cedes dysfunction as the intrinsic feature of MCD deﬁciency during in-
fancy, and that variable presentation in patients likely reﬂects dietary
and nutritional factors. These conclusions based on our biochemical
experimental data were reiterated by in silico metabolic modelling.
Our data presents a compelling narrative for the evolution of a cardi-
ac dysfunction phenotype in MCD deﬁciency. In the post-natal period
there is increased dependence on fatty acid oxidation concomitantwith the sudden increase in cardiac work and abundance of fatty acids
in the maternal milk supply [20]. Suckling represents an exclusively
high-fat diet (milk fromC57BL/6 dams is 42% fat [21]), thatMCD knock-
out mice are unable to fully utilize. This resulted in grossly abnormal
lipid accumulation as evidenced by increased body fat composition, dra-
matically elevated LV and liver triglyceride levels, and hyperlipidemic
serum. Intra-cardiac accumulation of triglyceride in MCD−/− hearts
may have direct toxic effects on cardiomyocytes, as previously de-
scribed in analogous models of fatty acid accumulation. For example,
carnitine-deﬁcient mice [22], high-fat feeding and streptozotocin in-
duced diabetes [23], where elevated LV triglyceride levels were linked
to poor survival, cell death and cardiac dysfunction [24]. In parallel,
we observe a reduced body weight, depleted tissue glycogen, and re-
duced serum lactate levels, which may be used as an alternative carbo-
hydrate source [25].
These changes are all indicative of a catabolic state and starvation
phenotype caused by the depletion of alternative substrates due to in-
ability to utilize fatty acids. Protein catabolism is suggested by amassive
increase in ketone bodies, which may exacerbate the phenotype by af-
fecting cellular fatty acid uptake [26], while high LDH and CK activities
reﬂectmuscle damage/breakdown. The failure to compensate via an in-
crease in PDH-mediated glucose oxidation is likely to be critical in the
evolution of energy depletion. In this regard, up-regulation of PDK4
mRNA is a particular maladaptation since it is a key inhibitor of PDH
Table 1
Morphometric and hemodynamic parameters of MCD−/− survivor mice.
Adult MCD+/+
(n = 6 F + 3 M)
Adult MCD−/−
(n = 6 F + 3 M)
P value
Age (weeks) 21 ± 2 21 ± 2 0.81
Organ weights
Body weight (g) 28.2 ± 1.7 29.5 ± 2.7 0.69
LV/body weight (mg/g) 2.72 ± 0.10 3.42 ± 0.20 0.006
RV/body weight (mg/g) 0.79 ± 0.10 0.99 ± 0.06 0.007
Lung/body weight (mg/g) 4.8 ± 0.8 4.8 ± 1.2 0.98
Liver weight/body
weight (mg/g)
42.9 ± 1.4 41.8 ± 1.5 0.63
Echocardiography
End diastolic area (mm2) 9.3 ± 0.4 10.6 ± 0.6 0.10
End systolic area (mm2) 3.2 ± 0.5 4.1 ± 0.8 0.39
Fractional area change (%) 66 ± 4 63 ± 5 0.65
Myocardial CSA (mm2) 10.8 ± 0.5 13.1 ± 0.7 0.02
PAAT (ms) 18.1 ± 1.3 17.7 ± 1.4 0.86
Hemodynamics
Heart rate (bpm) 505 ± 16 493 ± 20 0.66
LV systolic pressure (mm Hg) 98 ± 2 96 ± 2 0.50
LV end-diastolic pressure
(mm Hg)
6 ± 0.7 8 ± 0.9 0.12
dP/dtmax (mm Hg/s) 9929 ± 483 7769 ± 514 0.007
dP/dtmin (mm Hg/s) −9270 ± 589 −7105 ± 995 0.08
Tau (ms) 6.9 ± 0.4 9.1 ± 0.8 0.04
Stimulated dP/dtmax
(mm Hg/s)
13895 ± 957 10505 ± 1045 0.03
LV — left ventricular, RV — right ventricular, CSA — cross sectional area, and PAAT — pul-
monary artery acceleration time. All values are mean ± SEM. Comparisons were made
by Student's t-test. Stimulated dP/dt denotes value obtained during maximal stimulation
with dobutamine 16 ng/g BWt/min.
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ume as implied by reduced activity of citrate synthase.
The outcome is reduced adenine nucleotides in the heart, a state that
is usually only observed following acute ischemia or in chronic heart
failure, where levels correlate with severity of cardiac dysfunction [28].
The additional challenge of weaning, when pups are abruptly re-
moved from the dam, results in reduced caloriﬁc intake until pups
learn to take solid food. It is likely that this challenge is sufﬁcient to
kill many that are already energy starved. Weaning also represents an
abrupt change in dietary composition (42% fat content in milk to 4% in
chow). Surviving knockout mice appear to re-energise the heart on a
standard low-fat diet where 62% of the caloriﬁc value comes from car-
bohydrate, resulting in gradual resolution of cardiac dysfunction and
improving tissue lipid accumulation.4.1. In silico modelling
The abnormally high mortality in young MCD−/−mice meant that
there was very little adult tissue for metabolic phenotyping. For exam-
ple, we would have liked to measure exogenous substrate oxidation
(e.g. palmitate), but this typically requires n = 15 per group [6]. Since
we only obtained nine adult MCD−/− from 503 offspring, breeding suf-
ﬁcient mice for such experiments would be prohibitive. Thus to test the
hypothesis that changes in dietary substrate availability account for res-
olution of the MCD−/− phenotype, we used an established computer
model of cardiomyocyte metabolism [17] to simulate the switch from
maternal milk to standard laboratory chow. This approach has several
inherent limitations.
For example, no account was taken of developmental changes in ac-
tivity or expression of metabolic enzymes between young and adult
hearts, although this also represents an advantage, since it allowed us
to ask whether the change in substrate availability is, in itself, sufﬁcient
to improve the cardiac metabolic phenotype. The model takes no ac-
count of potential differences in neuroendocrine stimulation and there
may be species differences since the model is, by necessity, chimeric.
Simulated high-fat diet was based on published values for mouse milktaking into account plasma substrates measured in 18 day old mice.
Equivalent data was not available for adult mice and therefore low-fat
diet was based solely on the composition of chow with no account of
potential differences in bioavailability.
Despite these shortcomings, the use of the model is validated by re-
capitulation of our key experimental ﬁndings, e.g. triacylglyceride accu-
mulation and glycogen depletion under high-fat conditions, and is in
agreement with the previously published observations in MCD−/−
mice [29].
Moreover, the agreement between intermediate metabolic pheno-
type of MCD+/− simulations with the actual experimental ﬁndings
further validates the use of in silico modelling.
The modelling data indicates a move towards normalization of the
MCD−/− metabolic phenotype associated with an improvement in
cardiac efﬁciency when switched from milk to a standard chow diet.
This supports the hypothesis that dietary substrate availability is a
major determinant of the MCD deﬁciency phenotype.
4.2. Comparison with published MCD knockout phenotype
The level of early mortality observed here was not originally report-
ed in the MCD colony we obtained these mice from, despite having a
similar pathogen-free status and using identical chow. Nevertheless,
MCD gene deletion results in ~30% pre-weaning mortality in the origi-
nating MCD−/− colony (personal communication Prof Lopaschuk,
2014). One key difference between colonies is in breeding strategy,
where we used Het pairs to obtain a mix of genotypes, while Dyck
et al. used KO pair breeding. It is possible that MCD gene deletion alters
the fat composition of milk leading to MCD−/− dams providing a lower
fat load to suckling pups than the correspondingMCD+/−dams. Nor can
we exclude the possibility of differences in placental metabolite supply
in utero potentially predisposingMCD−/− toworse survival outcome. In
addition, MCD−/−mice are small and under-developed, therefore mice
in litters containing only knockouts do not have to compete with stron-
ger siblings for maternal milk supply. We planned to test this experi-
mentally, but after N18 months of breeding have failed to obtain the
necessary MCD−/− adult breeding pairs.
Another difference between the originatingMCD colony and theOx-
ford colony used in this study is the provenance of the C57BL/6 sub-
strain used for backcrossing. The Oxford colony is congenic to C56BL/
6J supplied by Harlan UK, whereas the Alberta colony is on a JAX™
C57BL/6 background from Charles River. The latter is known to have a
mutation in the Nnt (nicotinamide nucleotide transhydrogenase)
gene, which is unaffected in the Harlan UK sub-strain [30]. Nnt encodes
a mitochondrial protein that catalyses the production of NADPH and
mice with the Nnt mutation develop asymptomatic metabolic syn-
drome characterized by glucose intolerance and obesity-independent
reduced insulin secretion [31,32]. This genetic divergence may be one
of the factors contributing to the difference in survival between these
two colonies and it is likely that there will be other, as yet unidentiﬁed,
incidences of genetic drift between these C57BL/6J sub-strains.
Other environmental factors may also be important in deciding sur-
vival, e.g. litter size and husbandry practice at time of weaning. Never-
theless, by the time mice were fully adult, cardiac function was within
the normal range in agreement with the published literature [5–7].
4.3. MCD heterozygote phenotype and malonyl-CoA levels
It is notable thatmalonyl-CoA levels inMCD+/−micewere similar to
MCD−/−, yet MCD+/− had less triglyceride accumulation in the heart,
suggesting a limited ability to utilize fatty acids remained, and was suf-
ﬁcient tomaintain TANpool and normal cardiac function. Therefore, the
inhibition of CPT-1 bymalonyl-CoA is not the sole driver of theMCD−/−
phenotype and the loss of MCD protein itself is also relevant. This
suggests that alternative roles exist forMCD control of lipidmetabolism,
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located in cardiac peroxisomes [1,33].
4.4. Implication for human MCD and lipid oxidation deﬁciency syndromes
Our study demonstrates for the ﬁrst time that in early life cardiac
dysfunction is a consistent ﬁnding directly related to MCD deﬁciency,
and that variable penetrance of the phenotype in patients likely reﬂects
environmental factors linked to alternative substrate availability.Furthermore, our study suggests that heart screening should be a rou-
tine investigation in these patients, with extra monitoring focused on
times of enforced fasting, concurrent illness or major dietary change.
The structural, functional and metabolic changes observed in
MCD−/−mice at the post-weaning stage are characteristic of cardio-
myopathies caused by mitochondrial fatty acid metabolism defects
which typically manifest early in life and are associated with cardiac
remodelling, conduction defects and sudden onset of heart failure
[20,34,35]. For example, the observed metabolic phenotype has
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tional diets rich in fat and low in carbohydrate that result in high in-
fant mortality [36].
Currently, there are no established dietary and therapeutic manage-
ments for MCD deﬁciency disorder [12,37], we therefore propose that
MCD−/−mice would make a good model for future experimental stud-
ies. Furthermore, heterozygousMCD+/− animalwould be an interesting
model of mild MCD deﬁciency for future work.
4.5. Implications for therapeutic modulation of MCD
Pharmacological MCD inhibitors are under development e.g. for
treatment of cardiac ischaemia [6] and obesity [38]. Our study suggests
that caution is required with therapeutic inhibition of fatty acid oxida-
tion, a view further supported by a recent study in CPT-1 heterozygous
knockout mice subjected to aortic banding, which displayed mitochon-
drial abnormalities, lipid accumulation, and had greater functional
impairment and mortality compared to controls [39]. Whether there
are circumstances in which cardiac dysfunction may be induced by
MCD inhibition in an adult population merits further study.
5. Conclusion
This is the ﬁrst study to demonstrate that energy starvation and car-
diac insufﬁciency are intrinsic features of chronic MCD deﬁciency dur-
ing the suckling and peri-weaning period. It suggests that phenotype
severity likely depends on the composition of food intake and that
high-fat, low carbohydrate diets or periods of enforced fasting are par-
ticular risk factors. The MCD−/− mouse could represent a suitable
model to test therapeutic dietary modulation for patients with inborn
errors in fatty acid metabolism.
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